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surgery and 5 years of adjuvant tamoxifen to postoperative 
whole breast irradiation or no further therapy. At a median 
follow up of 5.7 years the local recurrence rate was reduced 
by RT from 4% to 1%. However there has been limited impact 
on practice.  A survey of Medicare patients (2) who met the 
eligibility criteria of the CALGB 9943 trial showed 
approximately a 3% reduction in use of adjuvant radiotherapy 
in a period following the publication of the 5 year results of 
the CALBG trial. The reasons for this limited impact on 
practice are uncertain.The 10 year results of the CALGB 9943 
(3) show that the difference in local control has widened(2% 
vs 9%). In the UK postoperative radiotherapy remains the 
standard of care for all patients technically suitable for 
radiotherapy irrespective of age and other clinico-
pathological risk factors. The benefits of adjuvant 
radiotherapy on local control have to be balanced against the 
issues of comorbidity, breast toxicity, risks of second 
malignancy(4) and the costs of radiotherapy. Results will be 
presented from the international PRIME 2 trial in over 1300 
hormone receptor positive, T1-2 (up to 3cm) pNO  breast 
cancer in women =/> 65 years treated by breast conserving 
surgery and adjuvant endocrine therapy with or without 
postoperative radiotherapy (5). A case can be made for 
offering selected older patients the option of the omission of 
RT. Techniques of partial breast irradiation are also being 
investigated which might be more convenient and less morbid 
than whole breast irradiation. 
There is limited level 1 evidence on the impact on quality of 
life of adjuvant radiotherapy. The PRIME quality of life trial 
suggests that there is no significant difference in global 
quality of life in early breast cancer patients treated by 
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Hypofractionation has lately been implemented as standard 
treatment in the adjuvant setting as well as in radical 
radiotherapy for various solid tumors such as in breast and 
lung carcinomas. Also for metastatic disease in the liver or 
brain, hypofractionated stereotactic radiotherapy has proven 
effective for both palliative purposes and sometimes cure. 
Palliative schedules have conventionally been designed to 
deliver sufficient radiation dose within a short period of time 
to achieve optimal palliation with particular consideration to 
life expectancy. Such treatment strategies may be assigned 
to frail and elderly patients at the expense of curative 
fractionation schedules, particularly for logistic reasons in 
those with impaired functional conditions, that the patient 
may better comply to treatment. However, data from 
DAHANCA showed no impact of age, comorbidity, or WHO 
performance status on delay of treatment in patients 
undergoing a fast-track work-up for head and neck cancer 
(H&N), and elderly patients (above 70) demonstrated 
equivalent compliance to prescribed radical radiation 
treatment compared to younger patients which was further 
translated into similar cancer-specific survival figures 
between the age-groups. However, if for a particular clinical 
reason a reduced treatment time is opted for in an the 
elderly H&N patient, several considerations should  be made. 
Whether the intention of treatment is palliative or curative, 
treatment volume and fractionation schedules are obviously 
related to toxicity. Elderly H&N patients with a low 
propensity for HPV-derived carcinomas have generally lower 
rates of neck metastases than younger patients (N0-1 below 
20% vs 35%) which defines a smaller target area. With modern 
diagnostic procedures and cone-beam based adaptive IMRT 
techniques, both dose-planning and execution of radiation 
treatment have become more precise which elderly patients 
may profit from, particularly if elective radiation is omitted, 
similar to stereotactic strategies. Delivery of 30 Gy in 10 
fraction over 2 weeks, or 20 Gy in 5 fx, confer a dose-
intensity much higher than conventional or accelerated 
regimens and, consequently, increases the risk of severe 
mucositis. We have adopted a hypofractionated schedule 
from the DAHANCA 2 trial consisting of 52 Gy in 13 fractions 
with two weekly fractions (8 Gy per week). This has secured 
a tolerable treatment schedule with a considerably high 
radiobiological dose for potential cure. Toxicity has been 
mild in comparison to standard fractionation, and the 
schedule has been employed for patients considered 
unsuitable for standard treatment. IMRT and VMAT are easily 
applied in hypofractionated regimens for elderly patients 
since these techniques have become standard of care, and 
acceptable toxicity and cure rates are expected. 
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Rapid population ageing in most area of the developed world 
substantially contributes to the significant increase in the 
cancer burden in the elderly. In the subgroup of cancer 
patients’ (pts) over-75 years of age, for ex, prostate cancer 
(PCa) becomes the most common tumour diagnosed in men in 
Europe and North America. On the other hand, life 
expectancy is increasing in western countries and this 
translates in a general feeling that curative treatment 
options should be offered even to elderly pts independently 
of their chronological age. Oncologists treating a geriatric 
population of pts face several major issues when developing 
